Orismilast for the Treatment of Mild to Severe Hidradenitis Suppurativa (OSIRIS)
Orismilast for the Treatment of Mild to Severe Hidradenitis Suppurativa (OSIRIS)
The purpose of this study is to assess the efficacy and safety of oral administration of orismilast for treatment of mild, moderate, or severe hidradenitis suppurativa (HS) in adults.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 24 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Patients will be graded and assigned to a severity group (mild, moderate, or severe). All groups will receive the same intervention
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Orismilast for the Treatment of Mild to Severe Hidradenitis Suppurativa (OSIRIS)
Estimated Study Start Date: August 1, 2021
Estimated Primary Completion Date: December 1, 2022
Estimated Study Completion Date: December 1, 2022
Arm:
- Experimental: Orismilast
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Estimated enrolment | 24 |
| Estimated Study start date | 01 August 2021 |
| Estimated Study Completion Date | 01 December 2022 |